VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma

On December 14, 2018, Posted by , In News, By , With Comments Off on VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma

VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the first patient has been dosed in a Phase I/II trial evaluating VXM01 oral immunotherapy in combination with avelumab*, a human anti-PD-L1 antibody, for the treatment of glioblastoma. The trial is part of a collaboration…

DKFZ/EMBL: Computer model to predict prostate cancer progress

On December 11, 2018, Posted by , In News, By , With Comments Off on DKFZ/EMBL: Computer model to predict prostate cancer progress

  IMAGE: Colourbox – Kiyoshi Takahase Segundo Cancer researchers have developed a computer model that can predict the course of disease for prostate cancer, based on cancer patient genomic and clinical data The model is currently being implemented at a prostate cancer clinic in Germany. The researchers have also found…

Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

On December 10, 2018, Posted by , In News, By , With Comments Off on Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

Data Confirm Clinical Single-Agent Activity of AFM13 in CD30-Positive Lymphoma with Cutaneous Presentation and Doubled Complete Response Rate of AFM13 in Combination with Keytruda® (Pembrolizumab) in Hodgkin Lymphoma Patients Future Combination Opportunities Include Combination of CD16A Immune Cell Engagers with Adoptive NK Cell Transfer Heidelberg, Germany, December 3, 2018 –…

A faster lane towards effective therapies of childhood brain cancer

On November 6, 2018, Posted by , In News, By ,, , With Comments Off on A faster lane towards effective therapies of childhood brain cancer

Scientists of the „Hopp Children’s Cancer Center at the NCT Heidelberg” (KiTZ), the German Cancer Consortium (DKTK) and the German Cancer Research Center (DKFZ), in collaboration with colleagues from Seattle, U.S.A., have built a collection of tumor models that can be used to test anticancer drugs for treating childhood brain…

DKFZ/HI-STEM – Breast cancer: Stress signaling promotes metastasis and therapy resistance

On November 6, 2018, Posted by , In News, By , , With Comments Off on DKFZ/HI-STEM – Breast cancer: Stress signaling promotes metastasis and therapy resistance

Scientists from the German Cancer Research Centre (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH) have identified a central switch protein in breast cancer that promotes tumor metastasis in response to cellular stress. The switch triggers a stem cell program in the cancer cells…

Immune oncology and beyond at the first joint BioRN and Ci3 Annual Conference

On October 26, 2018, Posted by , In Press Releases, By , , With Comments Off on Immune oncology and beyond at the first joint BioRN and Ci3 Annual Conference

Darmstadt, October 26, 2018 The BioRN Life Science Cluster Rhine-Neckar in Heidelberg and the Cluster for Individualized ImmuneIntervention (Ci3) in Mainz were the organizers of yesterday’s Joint BioRN & Ci3 Annual Conference titled “Immunotherapy and beyond – The next generation of cancer treatment“. 200 participants – members and partners of…

DKFZ: Takeda Oncology Research Award 2018 to Rocio Sotillo

On October 19, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: Takeda Oncology Research Award 2018 to Rocio Sotillo

A certain form of lung cancer is characterized by two genes that are accidentally fused. The fusion produces a growth signal for the cells. These tumors respond well to a targeted drug that deprives the cancer cells of the growth stimulus. Several molecular variants of cancer-promoting gene fusion exist. Rocio…

Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research

On October 15, 2018, Posted by , In News, By , , With Comments Off on Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research

Ready-to-use kits determine genomic characteristics of solid tumours Optimized workflow to generate results in house Software analysis allows correlation to AVENIO ctDNA NGS kits Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global commercial launch of three new next-generation sequencing (NGS) AVENIO Tumor Tissue Analysis Kits – the AVENIO…

Breast cancer: Towards individualized therapy

On October 8, 2018, Posted by , In News, By , , With Comments Off on Breast cancer: Towards individualized therapy

Breast cancer is as manifold as are those who are affected. Therefore, scientists and physicians from the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and the National Center for Tumor Diseases (NCT) in Heidelberg are generating genetic profiles from metastatic tissue samples before they choose, on this basis,…

Preclinical Efficacy Data of Apogenix’ HERA – CD27L Published in Frontiers in Oncology

On October 4, 2018, Posted by , In News, By , With Comments Off on Preclinical Efficacy Data of Apogenix’ HERA – CD27L Published in Frontiers in Oncology

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that new data published in the current volume of Frontiers in Oncology demonstrate the potent anti – tumor efficacy of Apogenix’ HERA – CD27L. In contrast to antibodies in development, HERA – CD27L is the first true CD27 receptor…